ReviewExperimental and therapeutic medicine2023
Mucormycosis diagnosis revisited: Current and emerging diagnostic methodologies for the invasive fungal infection (Review).
Review in Experimental and therapeutic medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Infection metallomics of pulmonary mucormycosis: multi-omics study of siderophore secretion, neutrophil recruitment, and lipid remodeling in rat lungs.Analytical and bioanalytical chemistry · 2026Article
- Article
- Delay in the Diagnosis of Osteoarticular Mucormycosis in Diabetic Ketoacidosis: A Learning Opportunity.Cureus · 2025Article
- Intra-abdominal Mucormycosis in an Immunocompetent Host: A Rare Presentation and Literature Review.Cureus · 2025Article
- The Black Fungus: A Rare Case of Pulmonary Mucormycosis.HCA healthcare journal of medicine · 2025Article
- Invasive Mucormycosis in a Chronic Lymphocytic Leukemia Patient on Zanubrutinib: A Case Report.Infection and drug resistance · 2025Article
- Article
- Diagnostic Value of Microbial Cell-free DNA Sequencing for Suspected Invasive Fungal Infections: A Retrospective Multicenter Cohort Study.Open forum infectious diseases · 2024Article
- Mucormycosis: A Rare disease to Notifiable Disease.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Review
- The SSS revolution in fungal diagnostics: speed, simplicity and sensitivity.British medical bulletin · 2023Article
- Atypical Skull-Base Osteomyelitis: Comprehensive Review and Multidisciplinary Management Viewpoints.Tropical medicine and infectious disease · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucormycosis, which is a life threatening condition, is one of the side effects experienced by post-COVID-19 patients. Early identification and timely treatment are essential to stop the dissemination of the disease, since invasive mucormycosis has a very high fatality rate and significant disease dispersion. Conventional diagnostic techniques, including clinical diagnosis, serology, histopathology and radiology, have limitations in diagnosing the disease at an early stage. This warrants the need for advanced diagnostic tools such as nucleic acid diagnostics, advanced serological tests (ELISpot), PCR (pan-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.